The PBM Breaking Point
Independent pharmacies across the country are walking away from pharmacy benefit manager contracts at a pace that would have been unthinkable a decade ago – and the model many are running toward, direct primary care, is reshaping what a neighborhood pharmacy can actually be.
Why Pharmacies Are Cutting Ties With PBMs
Pharmacy benefit managers – the middlemen who negotiate drug pricing between insurers, drug manufacturers, and pharmacies – have long held independent operators in a difficult position. PBMs set reimbursement rates that independent pharmacies must accept or lose access to the insured patient pool entirely. For years, independents accepted below-cost reimbursements on generic drugs and absorbed DIR (direct and indirect remuneration) fees that sometimes arrived months after a transaction, making cash flow nearly impossible to predict or plan around.
The math has simply stopped working for a growing number of operators. A pharmacy filling a 30-day supply of a common generic might receive a reimbursement from a PBM that falls below the pharmacy’s own acquisition cost. The DIR fee clawbacks, which PBMs deduct retroactively from pharmacies based on performance metrics, compounded the problem for years before federal rules began limiting the practice. Even with those reforms, the underlying reimbursement structure remains thin enough that many independents report margins that cannot sustain a full-service operation.
The consolidation happening inside PBM ownership is part of what’s pushing independents to the exit. The three largest PBMs – CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth Group) – collectively manage the majority of prescription drug claims in the United States. Each of those parent companies also owns retail pharmacy chains or pharmacy networks that compete directly with the independents they’re reimbursing. The conflict is structural, not incidental.
Some independent pharmacists describe the experience of being inside a PBM network as operating inside a system designed by a competitor. When a patient’s insurance directs them to a mail-order pharmacy or a chain location that shares ownership with their PBM, the independent down the street loses that prescription – and the PBM profits from both sides of the transaction. Walking away from those contracts is financially risky in the short term, but staying in has become a slow bleed for many.
Direct Primary Care as the Off-Ramp
Direct primary care, or DPC, originally took hold in the physician practice space as a membership-based model where patients pay a flat monthly fee directly to their doctor, bypassing insurance entirely for primary care services. What’s newer is pharmacies either partnering with DPC practices or building hybrid pharmacy-DPC models themselves, sometimes with a pharmacist-practitioner at the center of the care relationship.
The appeal for pharmacists is that DPC removes the PBM from the transaction altogether. In a direct-pay or membership model, the pharmacy negotiates drug pricing independently – often through buying groups or direct manufacturer relationships – and passes savings to patients without a PBM extracting a spread. For common maintenance medications, the cash price available through direct purchasing channels is frequently lower than the copay a patient would pay through insurance, which is a dynamic that surprises many patients when they first encounter it.
Chronic disease management is where the pharmacy-DPC hybrid gets particularly interesting. A pharmacist in a DPC arrangement can spend 30 to 45 minutes with a diabetic patient reviewing medication adherence, blood glucose logs, and lifestyle factors – the kind of clinical interaction that is structurally impossible in a high-volume insurance-driven pharmacy where the economics reward transaction speed over clinical depth. A growing number of states have expanded pharmacist scope of practice authority, allowing pharmacist practitioners to prescribe within defined protocols, which makes the clinical side of a DPC pharmacy model more viable.
The monthly membership fees in pharmacy-DPC hybrids typically cover dispensing services, clinical consultations, and sometimes a curated formulary of generics and over-the-counter products. Some models charge separately for medications at cost-plus pricing and bundle the clinical relationship into the membership. The specific structure varies, but the common thread is a direct financial relationship with the patient that cuts out the insurance intermediary for a defined scope of services. Patients who are uninsured or underinsured often find these arrangements cheaper than maintaining a prescription drug plan, particularly for predictable, ongoing medications.
Not every independent pharmacy can make the pivot. Practices heavily dependent on specialty drug dispensing or complex insurance billing – HIV medications, oncology supportive care, compounds requiring prior authorization – have different economics that don’t map cleanly onto a cash-pay model. And pharmacies in lower-income areas face real tension between a membership model that requires upfront payment and a patient population living paycheck to paycheck. The DPC path works best where the patient base has enough financial stability to trade a monthly fee for the promise of lower total costs and better access.
What the Shift Signals for Community Health
When an independent pharmacy exits a PBM network, the immediate concern is patient disruption – people who relied on that location and now face insurance coverage gaps or the hassle of switching. But the longer arc of this shift could produce something different: a tiered pharmacy landscape where PBM-network chains handle high-volume, insurance-dependent prescription filling while independent DPC-aligned pharmacies serve patients who want a clinical relationship and price transparency over convenience. That’s a real structural split, not a temporary market adjustment.
The pharmacies making this move are betting that patients, particularly those managing multiple chronic conditions, will pay for access to a pharmacist who knows their chart rather than a counter where they pick up a bag. Whether enough patients will make that choice, and pay for it, is the question that will determine whether this becomes a durable business model or a well-intentioned experiment that works for a narrow demographic and struggles everywhere else.
